The potential of CpG oligodeoxynucleotides as mucosal adjuvants - PubMed (original) (raw)
Affiliations
- PMID: 11642598
Review
The potential of CpG oligodeoxynucleotides as mucosal adjuvants
M J McCluskie et al. Crit Rev Immunol. 2001.
Abstract
The development of mucosal vaccines for humans has been hindered by the lack of safe yet effective mucosal adjuvants. Bacterial toxins are commonly used as adjuvants in animal models, but they are too toxic for use in humans. A novel class of adjuvant is CpG DNA, which contains unmethylated CpG dinucleotides in particular base contexts (CpG motifs). CpG DNA is most often coadministered with antigen in the form of synthetic oligodeoxynucleotides (CpG ODN), which are made with a nuclease-resistant phosphorothioate backbone. The vast majority of studies using CpG DNA as adjuvant have been with parenteral delivery; recently, however, mucosal immunization with CpG DNA as adjuvant has also been shown to induce both systemic (humoral and cellular) and mucosal antigen-specific immune responses. This review will highlight the recent uses of CpG DNA as an adjuvant at mucosal surfaces.
Similar articles
- The use of CpG DNA as a mucosal vaccine adjuvant.
McCluskie MJ, Weeratna RD, Payette PJ, Davis HL. McCluskie MJ, et al. Curr Opin Investig Drugs. 2001 Jan;2(1):35-9. Curr Opin Investig Drugs. 2001. PMID: 11527008 Review. - Novel strategies using DNA for the induction of mucosal immunity.
McCluskie MJ, Davis HL. McCluskie MJ, et al. Crit Rev Immunol. 1999;19(4):303-29. Crit Rev Immunol. 1999. PMID: 10530431 Review. - Enhancing vaccines with immune stimulatory CpG DNA.
Krieg AM, Davis HL. Krieg AM, et al. Curr Opin Mol Ther. 2001 Feb;3(1):15-24. Curr Opin Mol Ther. 2001. PMID: 11249727 Review. - CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases.
Klinman DM, Klaschik S, Sato T, Tross D. Klinman DM, et al. Adv Drug Deliv Rev. 2009 Mar 28;61(3):248-55. doi: 10.1016/j.addr.2008.12.012. Epub 2009 Jan 14. Adv Drug Deliv Rev. 2009. PMID: 19272313 Review. - The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides.
Weiner GJ. Weiner GJ. J Leukoc Biol. 2000 Oct;68(4):455-63. J Leukoc Biol. 2000. PMID: 11037965 Review.
Cited by
- CpG DNA assists the whole inactivated H9N2 influenza virus in crossing the intestinal epithelial barriers via transepithelial uptake of dendritic cell dendrites.
Yin Y, Qin T, Wang X, Lin J, Yu Q, Yang Q. Yin Y, et al. Mucosal Immunol. 2015 Jul;8(4):799-814. doi: 10.1038/mi.2014.110. Epub 2014 Dec 10. Mucosal Immunol. 2015. PMID: 25492476 - Alga-produced cholera toxin-Pfs25 fusion proteins as oral vaccines.
Gregory JA, Topol AB, Doerner DZ, Mayfield S. Gregory JA, et al. Appl Environ Microbiol. 2013 Jul;79(13):3917-25. doi: 10.1128/AEM.00714-13. Epub 2013 Apr 19. Appl Environ Microbiol. 2013. PMID: 23603678 Free PMC article. - Evaluation of TLR agonists as potential mucosal adjuvants for HIV gp140 and tetanus toxoid in mice.
Buffa V, Klein K, Fischetti L, Shattock RJ. Buffa V, et al. PLoS One. 2012;7(12):e50529. doi: 10.1371/journal.pone.0050529. Epub 2012 Dec 13. PLoS One. 2012. PMID: 23272062 Free PMC article. - A pilot study on developing mucosal vaccine against alveolar echinococcosis (AE) using recombinant tetraspanin 3: Vaccine efficacy and immunology.
Dang Z, Yagi K, Oku Y, Kouguchi H, Kajino K, Matsumoto J, Nakao R, Wakaguri H, Toyoda A, Yin H, Sugimoto C. Dang Z, et al. PLoS Negl Trop Dis. 2012;6(3):e1570. doi: 10.1371/journal.pntd.0001570. Epub 2012 Mar 27. PLoS Negl Trop Dis. 2012. PMID: 22479658 Free PMC article. - TLR ligands that stimulate the metabolism of vitamin D3 in activated murine dendritic cells can function as effective mucosal adjuvants to subcutaneously administered vaccines.
Enioutina EY, Bareyan D, Daynes RA. Enioutina EY, et al. Vaccine. 2008 Jan 30;26(5):601-13. doi: 10.1016/j.vaccine.2007.11.084. Epub 2007 Dec 26. Vaccine. 2008. PMID: 18178294 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical